Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B.
Maurer MJ, et al. Among authors: flament j.
Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.
Ann Oncol. 2018.
PMID: 29897404
Free PMC article.